Trials / Recruiting
RecruitingNCT06722170
A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss
A Study on the Safety, Tolerability, and Preliminary Efficacy of EH002 in the Treatment of DFNB9 Congenital Deafness
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Yilai Shu · Academic / Other
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
The study is designed to evaluate the safety, tolerability, and preliminary efficacy of EH002 for the treatment of congenital deafness caused by mutations in the OTOF gene. Participants may receive one or two injections of the EH002 gene therapy in one or both ears.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | EH002 administration | EH002 was administered into one or both ears via intracochlear injection. |
Timeline
- Start date
- 2024-11-22
- Primary completion
- 2027-11-01
- Completion
- 2029-11-01
- First posted
- 2024-12-09
- Last updated
- 2025-07-25
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06722170. Inclusion in this directory is not an endorsement.